Trials / Completed
CompletedNCT00785785
A Study of Nilotinib Versus Imatinib in GIST Patients
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 644 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib (AMN107) | |
| DRUG | imatinib (STI571) |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2008-11-05
- Last updated
- 2016-06-16
- Results posted
- 2016-04-07
Locations
165 sites across 35 countries: United States, Argentina, Austria, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT00785785. Inclusion in this directory is not an endorsement.